Tumour Markers and Kidney Function: A Systematic Review

Coppolino, Giuseppe; Bolignano, Davide; Rivoli, Laura; Mazza, Giuseppe; Presta, Pierangela; Fuiano, Giorgio

doi:10.1155/2014/647541

Cited by 42 publications

(35 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…albuminuria and eGFR) can improve the predictability of the existing models. As demonstrated in a recent meta-analysis, albuminuria, eGFR or both should be taken into consideration for prediction of cardiovascular events, being able to improve model performance for the prediction of all CV endpoints: CV mortality, coronary heart disease, stroke, heart failure (Cedillo-Couvert and Ricardo, 2016;Coppolino et al, 2014Matsushita et al, 2015). Moreover, when the CV events prediction accuracy of eGFR and albuminuria has been evaluated, it has been noted that the contribution of both these factors was similar, or even greater, than any traditional risk factor (Matsushita et al, 2015).…”

Section: Is Ckd a Risk Equivalent For Cardiovascular Events ?mentioning

confidence: 99%

Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer

Provenzano

Coppolino

Faga

et al. 2019

Reviews in Cardiovascular Medicine

View full text Add to dashboard Cite

This is an open access article under the CC BY-NC 4.0 license (https://creativecommons.org/licenses/by-nc/4.0/). Chronic kidney disease is a growing public health problem, as its prevalence and incidence have almost doubled over the last three decades. Chronic kidney disease is defined as the presence of an estimated glomerular filtration rate < 60 ml/min/1.73 m 2 and/or proteinuria ≥ 0.150 g/24 h. It has been demonstrated that both proteinuria and reduction in estimated glomerular filtration rate can predict the development of fatal and nonfatal cardiovascular events, regardless of traditional cardiovascular risk factors, namely blood pressure, smoking habit, cholesterol, age, gender. This relationship is found in the general population, high-risk cohorts and in patients referred to Nephrologists (tertiary care). The accuracy by which proteinuria or estimated glomerular filtration rate can predict these events, exceeds that obtained by the combination of all the other traditional risk factors. These important findings have led to chronic kidney disease being considered as a cardiovascular risk equivalent. Although this needs further investigation, a great effort has been made to reduce the cardiovascular risk in chronic kidney disease patients. Indeed, many clinical trials have been carried-out testing the effect of antihypertensive, proteinuria-lowering, lipid-lowering and hypoglycemic agents on cardiovascular risk protection. All these trials reduced, but did not eliminate, the overall cardiovascular risk. Future studies should be undertaken to identify high cardiovascular risk patients and novel therapeutic targets for cardiovascular protection in chronic kidney disease patients.

show abstract

Section: Is Ckd a Risk Equivalent For Cardiovascular Events ?mentioning

confidence: 99%

Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer

Provenzano

Coppolino

Faga

et al. 2019

Reviews in Cardiovascular Medicine

View full text Add to dashboard Cite

show abstract

“…Chromogranin A (CgA) is a 49 kDa protein synthesized in the chromaffin granules of the neuroendocrine cells (60). CgA levels are increased in those with neuroendocrine tumors, phaeochromocytomas, neuroblastomas, small cell lung cancer, and prostate cancers (60,61). Levels of CgA were found to have a close relationship with renal function using 99m Tc-DTPA clearance studies.…”

Section: Tumor Markers-chromogranin a And Tumor-associated Trypsin Inmentioning

confidence: 99%

Measuring Residual Renal Function in Hemodialysis Patients without Urine Collection

Wong

Kamal

Farrington

2016

Seminars in Dialysis

View full text Add to dashboard Cite

Many patients on hemodialysis retain significant residual renal function (RRF) but currently measurement of RRF in routine clinical practice can only be achieved using inter-dialytic urine collections to measure urea and creatinine clearances. Urine collections are difficult and inconvenient for patients and staff, and therefore RRF is not universally measured. Methods to assess RRF without reliance on urine collections are needed since RRF provides useful clinical and prognostic information and also permits the application of incremental hemodialysis techniques. Significant efforts have been made to explore the use of serum based biomarkers such as cystatin C, β-trace protein and β -microglobulin to estimate RRF. This article reviews blood-based biomarkers and novel methods using exogenous filtration markers which show potential in estimating RRF in hemodialysis patients without the need for urine collection.

show abstract

“…Unfortunately, such an ideal marker does not exist as yet. 3 Common tumor markers are described in the following sections.…”

Section: Definition Of Serum Tumor Markersmentioning

confidence: 99%

Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers

Amiri

2016

Renal Failure

View full text Add to dashboard Cite

Cancer is singled out as the biggest cause of death in the world, predicted to reach 13.1 million cancer-related deaths by the year 2030. Although there are no specific tumor markers used in cancer screening, some markers can be used to assist in making a diagnosis and determining a prognosis. They can be used to follow in cases where the diagnosis is cancer through monitoring of the disease recurrence and/or evaluating the response to therapy. These markers are not specific as the number increases in multiple cases of cancer. Some markers are positive in a single type of cancer; others are detectable in more than one type. An ideal tumor marker should be highly sensitive, specific, and reliable with high prognostic value. Other characteristics of an ideal tumor marker are organ specificity and correlation of it with tumor stages. However, none of the tumor markers reported to date has all these characteristics. Influence of different stages of chronic kidney function on serum tumor markers is variable. Furthermore, hemodialysis, peritoneal dialysis, and kidney transplantation affect on tumor markers differently. Sometimes, no study has been found in the literature review. Combined serum tumor markers may also be valuable. This literature review points the role of serum tumor markers in screening, diagnosis, and follow-up of cancer patients in chronic kidney disease patients and renal allograft recipients. In addition, impact of chronic kidney disease and kidney transplantation on different serum tumor markers is briefly explored.

show abstract

Tumour Markers and Kidney Function: A Systematic Review

Cited by 42 publications

References 82 publications

Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer

Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer

Measuring Residual Renal Function in Hemodialysis Patients without Urine Collection

Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers

Contact Info

Product

Resources

About